Evidence map›Paper›PMID 28574482›Full record

ArticleViruses2017

Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.

Chu Wang, Chunlai Jiang, Nan Gao, Kaikai Zhang, Donglai Liu, Wei Wang, Zhe Cong, Chuan Qin, Vitaly V Ganusov, Guido Ferrari and 5 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Chu WangNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China. wangchu13@mails.jlu.edu.cn.
Chunlai JiangNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China. jiangcl@jlu.edu.cn.
Nan GaoNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China. gaonan15@mails.jlu.edu.cn.
Kaikai ZhangNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China. vocebianca@yeah.net.
Donglai LiuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China. liudonglai@nifdc.org.cn.
Wei WangInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing 100021, China. wangw@cnilas.org.
Zhe CongInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing 100021, China. congz@cnilas.org.
Chuan QinInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing 100021, China. qinchuan@pumc.edu.cn.
Vitaly V GanusovDepartment of Microbiology, University of Tennessee, Knoxville, TN 37996, USA. vitaly.ganusov@gmail.com.
Guido FerrariDepartments of Surgery, Duke University Medical Center, Durham, NC 27710, USA. gflmp@duke.edu.
Celia LaBrancheDepartments of Surgery, Duke University Medical Center, Durham, NC 27710, USA. celia.labranche@duke.edu.
David C MontefioriDepartments of Surgery, Duke University Medical Center, Durham, NC 27710, USA. david.montefiori@duke.edu.
Wei KongNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China. weikong@mail.jlu.edu.cn.
Xianghui YuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China. xianghui@jlu.edu.cn.
Feng GaoNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, Jilin, China. fgao@duke.edu.
Jilin University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNDuke Medical Center · USUniversity of Tennessee at Knoxville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The suppression of viral loads and identification of selection signatures in non-human primates after challenge are indicators for effective human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) vaccines. To mimic the protective immunity elicited by attenuated SIV vaccines, we developed an integration-defective SIV (idSIV) vaccine by inactivating integrase, mutating sequence motifs critical for integration, and inserting the cytomegalovirus (CMV) promoter for more efficient expression in the SIVmac239 genome. Chinese rhesus macaques were immunized with idSIV DNA and idSIV particles, and the cellular and humoral immune responses were measured. After the intravenous SIVmac239 challenge, viral loads were monitored and selection signatures in viral genomes from vaccinated monkeys were identified by single genome sequencing. T cell responses, heterologous neutralization against tier-1 viruses, and antibody-dependent cellular cytotoxicity (ADCC) were detected in idSIV-vaccinated macaques post immunization. After challenge, the median peak viral load in the vaccine group was significantly lower than that in the control group. However, this initial viral control did not last as viral set-points were similar between vaccinated and control animals. Selection signatures were identified in Nef, Gag, and Env proteins in vaccinated and control macaques, but these signatures were different, suggesting selection pressure on viruses from vaccine-induced immunity in the vaccinated animals. Our results showed that the idSIV vaccine exerted some pressure on the virus population early during the infection but future modifications are needed in order to induce more potent immune responses.

Indexed as

Immunity, CellularImmunity, HumoralVirus IntegrationAdministration, IntravenousAnimalsAntibodies, NeutralizingAntibodies, ViralAntibody-Dependent Cell CytotoxicityMacaca mulattaSAIDS VaccinesSimian Immunodeficiency VirusVaccines, AttenuatedViral LoadAntibodies, NeutralizingAntibodies, ViralSAIDS VaccinesVaccines, Attenuatedchallengeintegration defectionsingle genome sequencingSIVvaccine

Identifiers

PMID28574482
PMCPMC5490812
OpenAlexW2620862245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.